Exhibit 99.1

                PDI Files Action Against Cellegy Pharmaceuticals

Upper Saddle River, NJ-- (December 14, 2003) PDI, Inc. (NASDAQ: PDII) announced
that on Friday, December 12, 2003, it instituted an action against Cellegy
Pharmaceutical, Inc. in the U.S. District Court for the Southern District of New
York seeking to rescind the Fortigel License Agreement on the grounds that it
was procured by fraud and for damages resulting from the breach of that
agreement by Cellegy. PDI is seeking return of the license fee paid by PDI on
December 31, 2002 of $15 million plus additional damages caused by Cellegy's
conduct.

About PDI

PDI, a premier healthcare sales and marketing company, provides strategic
alternatives to the portfolio challenges of biopharmaceutical and medical device
and diagnostics manufacturers. Focusing on two core businesses, sales and
marketing services and product commercialization, PDI leverages its expertise
and commercial infrastructure to maximize profitable brand growth. Manufacturers
choose the relationship which best meets their strategic and financial
objectives, ranging from individual or bundled service agreements to broader
commercial partnerships.

For more information, visit the Company's website at www.pdi-inc.com.

This press release contains forward-looking statements. Investors are cautioned
that these forward-looking statements are subject to numerous risks and
uncertainties, known and unknown, which could cause actual results and
developments to differ materially from those expressed or implied in such
statements. Please see the risk factors detailed from time to time in PDI's
periodic filings with the Securities and Exchange Commission, including without
limitation, PDI's Annual Report on Form 10-K for the year ended December 31,
2002, and PDI's periodic reports on Forms 10-Q and 8-K filed with the Securities
and Exchange Commission since January 1, 2003. The forward looking-statements in
this press release are based upon management's reasonable belief as of the date
hereof. PDI undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.